AstraZeneca PLC Files Form 6-K

TL;DR

AZN filed a 6-K, standard foreign issuer report. Nothing new, just housekeeping.

AI Summary

AstraZeneca PLC filed a Form 6-K on August 21, 2025, reporting its status as a foreign issuer. The filing indicates that AstraZeneca is submitting its reports under Form 20-F. The company's principal executive offices are located at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.

Why It Matters

This filing is a routine report for foreign issuers, confirming their reporting obligations and providing updated corporate information to the SEC and investors.

Risk Assessment

Risk Level: low — This is a routine administrative filing by a foreign issuer and does not contain new material financial or operational information.

Key Players & Entities

• AstraZeneca PLC (company) — Filer of the report
• 001-11960 (company) — SEC File Number
• 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom (company) — Company address
• 20250821 (date) — Filing date

FAQ

From the Filing

0001654954-25-009884.txt : 20250821 0001654954-25-009884.hdr.sgml : 20250821 20250821105120 ACCESSION NUMBER: 0001654954-25-009884 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250821 FILED AS OF DATE: 20250821 DATE AS OF CHANGE: 20250821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASTRAZENECA PLC CENTRAL INDEX KEY: 0000901832 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11960 FILM NUMBER: 251239088 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA BUSINESS PHONE: 011 44 20 7304 5000 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: 1 FRANCIS CRICK AVENUE STREET 2: CAMBRIDGE BIOMEDICAL CAMPUS CITY: CAMBRIDGE PROVINCE COUNTRY: X0 ZIP: CB2 0AA FORMER COMPANY: FORMER CONFORMED NAME: ZENECA GROUP PLC DATE OF NAME CHANGE: 19930422 6-K 1 a2511w.htm HOLDING(S) IN COMPANY a2511w FORM 6-K   SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Report of Foreign Issuer   Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934   For the month of August 2025   Commission File Number: 001-11960   AstraZeneca PLC   1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F X Form 40-F __   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):   Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______   Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.   Yes __ No X   If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________         AstraZeneca PLC   INDEX TO EXHIBITS     1. Holding(s) in Company   TR-1: Standard form for notification of major holdings   1. Issuer Details   ISIN GB0009895292   Issuer Name ASTRAZENECA PLC   UK or Non-UK Issuer UK   2. Reason for Notification   An acquisition or disposal of voting rights   3. Details of person subject to the notification obligation   Name The Capital Group Companies, Inc.   City of registered office (if applicable) Los Angeles   Country of registered office (if applicable) USA   4. Details of the shareholder   Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above       City of registered office (if applicable)       Country of registered office (if applicable)       5. Date on which the threshold was crossed or reached   19-Aug-2025   6. Date on which Issuer notified   20-Aug-2025   7. Total 9. Information in relation to the person subject to the notification obligation     % of voting rights attached to shares (total of 8.A) % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) Total of both in % (8.A + 8.B) Total number of voting rights held in issuer Resulting situation on the date on which threshold was crossed or reached   4.997854   0.000000   4.997854   77500852   Position of previous notification (if applicable)   5.009591   0.000000   5.009591       8. Notified detai